Patents by Inventor Kirstin Zettlitz

Kirstin Zettlitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
    Publication number: 20240026025
    Abstract: This invention relates to inhibition of the N-cadherin signaling using a humanized anti-N-cadherin antibody. In one embodiment, the invention relates to methods of treating an N-cadherin-mediated disease or N-cadherin-mediated disorder in a subject by contacting the subject with an anti-N-cadherin antibody.
    Type: Application
    Filed: June 8, 2023
    Publication date: January 25, 2024
    Inventors: Kirstin A. Zettlitz, Anna M. Wu, Robert E. Reiter
  • ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF
    Publication number: 20230181772
    Abstract: Disclosed are engineered anti-prostate stem cell antigen (PSCA) fusion proteins and uses thereof to detect and treat cancers expressing PSCA.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 15, 2023
    Applicants: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. WU, Kirstin A. ZETTLITZ, Robert E. REITER
  • Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof
    Patent number: 10689452
    Abstract: The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: June 23, 2020
    Assignees: UNIVERSITÄT STUTTGART, BALIOPHARM AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Fabian Richter, Kirstin Zettlitz, Peter Scheurich, Andreas Herrmann
  • HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
    Publication number: 20200165351
    Abstract: This invention relates to inhibition of the N-cadherin signaling using a humanized anti-N-cadherin antibody. In one embodiment, the invention relates to methods of treating an N-cadherin-mediated disease or N-cadherin-mediated disorder in a subject by contacting the subject with an anti-N-cadherin antibody.
    Type: Application
    Filed: June 6, 2018
    Publication date: May 28, 2020
    Inventors: Kirstin A. Zettlitz, Anna M. Wu, Robert E. Reiter
  • MONOVALENT INHIBITOR OF huTNFR1 INTERACTION
    Publication number: 20190144555
    Abstract: The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.
    Type: Application
    Filed: April 4, 2017
    Publication date: May 16, 2019
    Inventors: Roland KONTERMANN, Klaus PFIZENMAIER, Fabian RICHTER, Kirstin ZETTLITZ, Peter SCHEURICH, Andreas HERRMANN
  • Anti-huTNFR1 antibody and methods of use thereof for treatment
    Patent number: 8859739
    Abstract: The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 14, 2014
    Assignee: Baliopharm AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Andreas Herrmann, Kirstin Zettlitz
  • ANTI-huTNFR1 ANTIBODY
    Publication number: 20130251707
    Abstract: The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.
    Type: Application
    Filed: September 16, 2011
    Publication date: September 26, 2013
    Applicant: BALIOPHARM AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Andreas Herrmann, Kirstin Zettlitz